No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BMY Bristol-Myers Squibb
- 44.700
- -4.160-8.51%
Close Apr 25 16:00 ET
- 44.930
- +0.230+0.51%
Pre 07:15 ET
90.61BMarket Cap-14419P/E (TTM)
47.500High44.370Low45.07MVolume47.390Open48.860Pre Close2.03BTurnover2.23%Turnover Ratio11.58P/E (Static)2.03BShares66.25352wk High5.49P/B90.41BFloat Cap44.37052wk Low2.34Dividend TTM2.02BShs Float76.835Historical High5.23%Div YieldTTM6.41%Amplitude8.510Historical Low45.093Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Trending: Bristol Myers Squibb Cuts '24 EPS Outlook, Plans Job Cuts in Cost Saving Efforts
10:19 ET--Bristol Myers Squibb is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. The drugmaker reported a first-quarter loss of
Express News | Bristol-Myers Squibb Co : BMO Cuts Target Price to $48 From $55
Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma -- WSJ
By David Wainer Bristol-Myers Squibbs market capitalization has dropped so much over the past year that it is now arguably no longer part of the big pharma club. After reporting disappointing earnin
Express News | Chmp Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (Nivolumab) in Combination With Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients With Unresectable or Metastatic Urothelial Carcinoma
Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), Laboratory (LH) and Bristol-Myers Squibb (BMY)
Bristol-Myers Squibb: Hold Rating Amid Mixed Performance and Future Revenue Concerns
Comments
FDA PDUFA Update…
🗓️ Last week’s PDUFAs:
$Supernus Pharmaceuticals(SUPN.US$ : CRL 4/8/24 🙁
⇒ SPN-830
⇒ OFF episodes in PD
⇒ NDA
⇒ PDUFA: 4/5/24
$Legend Biotech(LEGN.US$ & $Johnson & Johnson(JNJ.US$ : Approved 🎉
⇒ CARVYKTI (cilta-cel)
⇒ Multiple myeloma
⇒ sBLA
⇒ PDUFA: 4/5/24
$AstraZeneca(AZN.US$ : Approved 🎉
⇒ Enhertu
⇒ HER2+ solid tumors
⇒ sBLA
⇒ PDUFA: Q2 2024
$2seventy bio(TSVT.US$ & $Bristol-Myers Squibb(BMY.US$ : Approved 🎉
⇒ Abecma
⇒ Multiple myeloma
⇒ sBLA
⇒ Delayed PDUFA
$Vanda Pharmaceuticals(VNDA.US$...
$Supernus Pharmaceuticals(SUPN.US$ : CRL 4/8/24 🙁
⇒ SPN-830
⇒ OFF episodes in PD
⇒ NDA
⇒ PDUFA: 4/5/24
$Legend Biotech(LEGN.US$ & $Johnson & Johnson(JNJ.US$ : Approved 🎉
⇒ CARVYKTI (cilta-cel)
⇒ Multiple myeloma
⇒ sBLA
⇒ PDUFA: 4/5/24
$AstraZeneca(AZN.US$ : Approved 🎉
⇒ Enhertu
⇒ HER2+ solid tumors
⇒ sBLA
⇒ PDUFA: Q2 2024
$2seventy bio(TSVT.US$ & $Bristol-Myers Squibb(BMY.US$ : Approved 🎉
⇒ Abecma
⇒ Multiple myeloma
⇒ sBLA
⇒ Delayed PDUFA
$Vanda Pharmaceuticals(VNDA.US$...
10
1
Major acquisition announced YTD in 2024
A look at one of the major acquisition deals YTD…👇
$MRTX
Acquired By: Bristol-Myers Squibb$Bristol-Myers Squibb(BMY.US$
Date: Jan. 23, 2024
Price: $4.8B
$AbbVie(ABBV.US$$GlaxoSmithKline(GSK.US$
$MRTX
Acquired By: Bristol-Myers Squibb$Bristol-Myers Squibb(BMY.US$
Date: Jan. 23, 2024
Price: $4.8B
$AbbVie(ABBV.US$$GlaxoSmithKline(GSK.US$
4
1
Updated Complete & Utter M&A Guesses Purely for Entertainment Purposes:
$SPDR S&P Biotech ETF(XBI.US$
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x %$Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x %$Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
2
$Eledon Pharmaceuticals(ELDN.US$ 10%🟢
First-ever Transplant of Genetically Modified Kidney
⇒ Pig to a Human
⇒ Use of Tegoprubart (anti-CD40L antibody)
⇒ Immunosuppressive treatment
$Bristol-Myers Squibb(BMY.US$
⇒ First CAR T Cell Therapy approval in the EU
⇒ Abecma
First-ever Transplant of Genetically Modified Kidney ⇒ Pig to a Human
⇒ Use of Tegoprubart (anti-CD40L antibody)
⇒ Immunosuppressive treatment
$Bristol-Myers Squibb(BMY.US$
⇒ First CAR T Cell Therapy approval in the EU
⇒ Abecma
3
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Ginvest : Thank you for the timely info